Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mayne Pharma Group Ltd Announces FDA Approval Of New 200mg Doryx Tablet


Thursday, 11 Apr 2013 09:04pm EDT 

Mayne Pharma Group Ltd announced that the US Food and Drug Administration (FDA) has approved a 200mg strength of Doryx (doxycycline hyclate) Delayed-Release Tablet. Warner Chilcott, the Company’s marketing and distribution partner of Doryx in the US, is expected to commence launch of this product by July 2013. Doryx Delayed-Release Tablets are a tetracycline-class oral antibiotic. 

Company Quote

0.9
0.0050 +0.56%
24 Jul 2014